LJH685 is potent pan-RSK inhibitor that targets RSK N-terminal kinase domain (NTKD) ATP-binding site (IC50/[ATP] = 6 nM/5 μM/RSK1, 5 nM/20 μM/RSK2, 4 nM/10 μM/RSK3). LJI308 effectivelfy inhibits MAPK pathway-dependent cancer growth (EC50 values of 0.73 μM/MDA-MB-231 and 0.79 μM/H358) by reducing the phosphorylation level of cellular Y-box binding protein-1 (YB1) Ser102 (EC50 = 0.2-0.3 μM; MDA-MB-231 and H358), but not that of ribosomal S6 protein (S6RP) S235/236.
NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA, 95111733, human lung (bronchoalveolar), Not specified
assay
≥98% (HPLC)
assay
≥98% (HPLC)
assay
≥95% (HPLC)
assay
-
form
powder
form
powder
form
lyophilized powder
form
-
Quality Level
100
Quality Level
100
Quality Level
-
Quality Level
-
storage temp.
2-8°C
storage temp.
−20°C
storage temp.
−20°C
storage temp.
−196°C
solubility
DMSO: 2 mg/mL, clear (Warmed)
solubility
DMSO: 5 mg/mL, clear (warmed)
solubility
-
solubility
-
color
white to beige
color
white to beige
color
-
color
-
Lagerklasse
11 - Combustible Solids
Was ist los?
WGK 3
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Hier finden Sie alle aktuellen Versionen:
Analysenzertifikate (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.
Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.